Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ABUS 
Arbutus Biopharma Corp (ABUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ABUS (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 5.57% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 620.40M USD | Price to earnings Ratio - | 1Y Target Price 5.41 |
Price to earnings Ratio - | 1Y Target Price 5.41 | ||
Volume (30-day avg) 1144882 | Beta 1.45 | 52 Weeks Range 2.63 - 4.72 | Updated Date 04/24/2025 |
52 Weeks Range 2.63 - 4.72 | Updated Date 04/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-04-30 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -995.43% |
Management Effectiveness
Return on Assets (TTM) -33.36% | Return on Equity (TTM) -68.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 497147007 | Price to Sales(TTM) 100.53 |
Enterprise Value 497147007 | Price to Sales(TTM) 100.53 | ||
Enterprise Value to Revenue 80.56 | Enterprise Value to EBITDA -5.64 | Shares Outstanding 191480000 | Shares Floating 136309001 |
Shares Outstanding 191480000 | Shares Floating 136309001 | ||
Percent Insiders 21.9 | Percent Institutions 54.96 |
Analyst Ratings
Rating 4.2 | Target Price 5.08 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Arbutus Biopharma Corp
Company Overview
History and Background
Arbutus Biopharma Corp. (ABUS) was founded in 2003 (originally Protiva Biotherapeutics) and is dedicated to discovering, developing, and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. Significant milestones include licensing agreements with pharmaceutical companies and advancing its pipeline of HBV-targeting therapeutics.
Core Business Areas
- HBV Therapies: Focuses on developing novel therapies targeting various stages of the HBV lifecycle to achieve functional cures.
Leadership and Structure
The leadership team consists of William Collier (President and CEO), Michael J. Sofia (Chief Scientific Officer), and other key executives. The organizational structure is typical of a biotechnology company, with departments focusing on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- AB-729: AB-729 is an RNAi therapeutic designed to reduce all HBV viral proteins and HBsAg. It is being developed in combination with other agents as part of a curative regimen. Competitors include Vir Biotechnology (VIR) and Assembly Biosciences (ASMB) who are developing similar HBV therapies.
- AB-101: AB-101 is a novel oral PD-L1 inhibitor and a component of Arbutus' combination therapy to cure HBV. Competitors include Bristol Myers Squibb and Roche, which are developing similar agents.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. The HBV therapeutics market is driven by the need for effective treatments for chronic HBV infection.
Positioning
Arbutus Biopharma Corp is positioned as a research and development-focused company specializing in HBV therapies. Its competitive advantage lies in its innovative technologies targeting multiple aspects of the HBV lifecycle.
Total Addressable Market (TAM)
The global hepatitis B therapeutics market is projected to reach billions of dollars. Arbutus is positioned to capture a significant portion of this TAM with its novel therapies if they are approved.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio in HBV therapies
- Experienced management team
- Focus on innovative technologies
- Partnerships with leading pharmaceutical companies
Weaknesses
- Reliance on pipeline progress
- High cash burn rate
- Susceptibility to clinical trial failures
- Limited commercial infrastructure
Opportunities
- Potential for breakthrough HBV therapies
- Expanding market for HBV treatments in developing countries
- Strategic collaborations and licensing agreements
- Advancements in RNAi and immunotherapy technologies
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and approval delays
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- VIR
- ASMB
- BMY
- GILD
Competitive Landscape
Arbutus Biopharma Corp faces competition from larger pharmaceutical companies with more resources. However, its specialized focus on HBV therapies and innovative technologies provide a competitive edge.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to pipeline advancements and strategic collaborations. The company's growth potential is largely dependent on the success of its HBV therapy programs.
Future Projections: Future growth projections depend on clinical trial outcomes and regulatory approvals. Analyst estimates vary but generally anticipate significant revenue potential if key programs are successful.
Recent Initiatives: Recent initiatives include advancing clinical trials for AB-729 and AB-101, expanding partnerships, and strengthening the intellectual property portfolio.
Summary
Arbutus Biopharma is a high-risk, high-reward biotech company focused on HBV cures. The company has a strong intellectual property portfolio. The company needs to be vigilant about competition and funding. Success is contingent on positive clinical trial results.
Similar Companies
ASMB
Assembly Biosciences Inc
ASMB
Assembly Biosciences Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Analyst reports, Industry publications, Company website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arbutus Biopharma Corp
Exchange NASDAQ | Headquaters Warminster, PA, United States | ||
IPO Launch date 2015-08-03 | President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.arbutusbio.com |
Full time employees 44 | Website https://www.arbutusbio.com | ||
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.